Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial

The Lancet Infectious Diseases

Volumn 16, Issue 1, 2016, Pages 61-69

  Phyo, Aung Pyae ^a,b,c   Jittamala, Podjanee ^b   Nosten, François H ^a,b,c   Pukrittayakamee, Sasithon ^b   Imwong, Mallika ^b   White, Nicholas J ^b,c   Duparc, Stephan ^d   Macintyre, Fiona ^d   Baker, Mark ^d   Möhrle, Jörg J ^d  

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Medicines for Malaria Venture   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIMALARIAL AGENT; ARTEFENOMEL; ARTESUNATE PLUS MEFLOQUINE; ASPARTATE AMINOTRANSFERASE; CHLOROQUINE PLUS PRIMAQUINE; CREATINE KINASE; ADAMANTANE; OZ 439; PEROXIDE;

ABNORMAL LABORATORY RESULT; ADULT; ANTIMALARIAL ACTIVITY; ARTICLE; COHORT ANALYSIS; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ELECTROCARDIOGRAPH; EXPLORATORY RESEARCH; FEMALE; FEVER; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PARASITEMIA; PERICARDITIS; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; QT PROLONGATION; THAILAND; TREATMENT OUTCOME; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HALF LIFE TIME; MALARIA, FALCIPARUM; MALARIA, VIVAX; MIDDLE AGED; MULTICENTER STUDY; YOUNG ADULT;

ADAMANTANE; ADOLESCENT; ADULT; ANTIMALARIALS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; MALARIA, FALCIPARUM; MALARIA, VIVAX; MALE; MIDDLE AGED; PEROXIDES; THAILAND; YOUNG ADULT;

EID: 84964384823     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00320-5     Document Type: Article

References (46)

1. WHO. World malaria report. http://www.who.int/malaria/publications/world_malaria_report/en/, 2014 (accessed Sept 8, 2015).
2. WHO. Guidelines for the treatment of malaria, third edition. http://www.who.int/malaria/publications/atoz/9789241549127/en/, 2015 (accessed Sept 8, 2015).
3. Ashley, EA, White, NJ, Artemisinin-based combinations. Curr Opin Infect Dis 18 (2005), 531–536.
4. , PM, O'Neill, Barton, VE, Ward, SA, The molecular mechanism of action of artemisinin—the debate continues. Molecules 15 (2010), 1705–1721.
5. Krishna, S, Bustamante, L, Haynes, RK, et al. Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 29 (2008), 520–527.
6. Nosten, F, White, NJ, Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 77:suppl (2007), 181–192.
7. Onyango, EO, Ayodo, G, Watsierah, CA, et al. Factors associated with non-adherence to artemisinin-based combination therapy (ACT) to malaria in a rural population from holoendemic region of western Kenya. BMC Infect Dis, 12, 2012, 143.
8. Lin, JT, Juliano, JJ, Wongsrichanalai, C, Drug-resistant malaria: the era of ACT. Curr Infect Dis Rep 12 (2010), 165–173.
9. Ashley, EA, Dhorda, M, Fairhurst, RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371 (2014), 411–423.
10. Tun, KM, Imwong, M, Lwin, KM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis 15 (2015), 415–421.
11. Leang, R, Taylor, WR, Bouth, DM, et al. Evidence of falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother 59 (2015), 4719–4726.
12. Wells, TNC, Hooft van Huijsduijnen, R, Van Voorhis, WC, Malaria medicines: a glass half full?. Nat Rev Drug Discov 14 (2015), 424–442.
13. 2+-mediated decomposition, PfATP6 binding, and antimalarial activities of artemisone and other artemisinins: the unlikelihood of C-centered radicals as bioactive intermediates. ChemMedChem 2 (2007), 1480–1497.
14. Vennerstrom, JL, Arbe-Barnes, S, Brun, R, et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430 (2004), 900–904.
15. Wells, TN, Alonso, PL, Gutteridge, WE, New medicines to improve control and contribute to the eradication of malaria. Nat Rev Drug Discov 8 (2009), 879–891.
16. Saha, N, Moehrle, JJ, Zutshi, A, et al. Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects. J Clin Pharmacol 54 (2014), 386–393.
17. Valecha, N, Looareesuwan, S, Martensson, A, et al. Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial. Clin Infect Dis 51 (2010), 684–691.
18. Valecha, N, Krudsood, S, Tangpukdee, N, et al. Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial. Clin Infect Dis 55 (2012), 663–671.
19. Gautam, A, Ahmed, T, Sharma, P, et al. Pharmacokinetics and pharmacodynamics of arterolane maleate following multiple oral doses in adult patients with P falciparum malaria. J Clin Pharmacol 51 (2011), 1519–1528.
20. Patil, C, Katare, S, Baig, M, et al. Fixed dose combination of arterolane and piperaquine: a newer prospect in antimalarial therapy. Ann Med Health Sci Res 4 (2014), 466–471.
21. Moehrle, JJ, Duparc, S, Siethoff, C, et al. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol 75 (2013), 524–537.
22. Charman, SA, Arbe-Barnes, S, Bathurst, IC, et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci USA 108 (2011), 4400–4405.
23. Darpo, B, Ferber, G, Siegl, P, et al. Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria. Br J Clin Pharmacol, 2015, 10.1111/bcp.12680 published online May 13.
24. Lwin, KM, Imwong, M, Suangkanarat, P, et al. Elimination of Plasmodium falciparum in an area of multi-drug resistance. Malar J, 14, 2015, 319.
25. PATH. A guide to fluorescent spot testing for G6PD deficiency. http://sites.path.org/dx/files/2012/04/FST-Guidebook.pdf, 2014 (accessed Sept 8, 2015).
26. Flegg, JA, Guerin, PJ, White, NJ, et al. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J, 10, 2011, 339.
27. Tabernero, P, Newton, PN, The WWARN antimalarial quality surveyor. Pathog Glob Health 106 (2012), 77–78.
28. Woodrow, CJ, Dahlström, S, Cooksey, R, et al. High-throughput analysis of antimalarial susceptibility data by the Worldwide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool. Antimicrob Agents Chemother 57 (2013), 3121–3130.
29. Brown, EG, Wood, L, Wood, S, The medical dictionary for regulatory activities (MedDRA). Drug Saf 20 (1999), 109–117.
30. Ariey, F, Witkowski, B, Amaratunga, C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505 (2014), 50–55.
31. Morris, CA, Duparc, S, Borghini-Fuhrer, I, et al. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J, 10, 2011, 263.
32. Tarning, J, Rijken, MJ, McGready, R, et al. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob Agents Chemother 56 (2012), 1997–2007.
33. Hong, X, Liu, CH, Huang, XT, et al. Pharmacokinetics of dihydroartemisinin in Artekin tablets for single and repeated dosing in Chinese healthy volunteers. Biopharm Drug Dispos 29 (2008), 237–244.
34. Carrara, VI, Lwin, KM, Phyo, AP, et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: an observational study. PLoS Med, 10, 2013, e1001398.
35. Denis, MB, Tsuyuoka, R, Lim, P, et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health 11 (2006), 1800–1807.
36. Carrara, VI, Zwang, J, Ashley, EA, et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One, 4, 2009, e4551.
37. Leang, R, Barrette, A, Bouth, DM, et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother 57 (2013), 818–826.
38. Leang, R, Ros, S, Duong, S, et al. Therapeutic efficacy of fixed dose artesunate-mefloquine for the treatment of acute, uncomplicated Plasmodium falciparum malaria in Kampong Speu, Cambodia. Malar J, 12, 2013, 343.
39. Da Costa, D, Brady, WJ, Edhouse, J, Bradycardias and atrioventricular conduction block. BMJ 324 (2002), 535–538.
40. Beg, M, Ahmad, S, Tamanna, Z, et al. Severe malaria presenting as complete heart block. J Indian Acad Clin Med 7 (2006), 58–60.
41. White, NJ, Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 7 (2007), 549–558.
42. Biot, C, Nosten, F, Fraisse, L, et al. The antimalarial ferroquine: from bench to clinic. Parasite 18 (2011), 207–214.
43. Wani, WA, Jameel, E, Baig, U, et al. Ferroquine and its derivatives: new generation of antimalarial agents. Eur J Med Chem 101 (2015), 534–551.
44. Tarning, J, Lindegardh, N, Lwin, KM, et al. Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria. Antimicrob Agents Chemother 58 (2014), 2052–2058.
45. Tarning, J, Thana, P, Phyo, AP, et al. Population pharmacokinetics and antimalarial pharmacodynamics of piperaquine in patients with Plasmodium vivax malaria in Thailand. CPT: Pharmacometrics Syst Pharmacol, 3, 2014, e132.
46. Phillips, MA, Lotharius, J, Marsh, K, et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Transl Med, 7, 2015, 296ra111.